A new survey from Health Union, Cystic Fibrosis In America 2019, finds that people with the condition who currently use a cystic fibrosis transmembrane conductance regulator (CFTR) modulator tend to have a more positive view about their futures, treatment plans and healthcare professional relationships than those who have never used one.

For many chronic conditions, obtaining a formal IBS diagnosis can lead to validation and relief, allowing the patient to then find an effective treatment. With IBS, however, this does not appear to be the case. Since 2017, annual IBS In America statistics have shown an increased rate of formal diagnosis from a healthcare professional year over year, with 90% of respondents reporting a formal diagnosis in 2019 up from 87% in 2018.

Health Union will share research findings based on data and experience from three of the company’s oncology-specific online health communities in presentations at the American Public Health Association (APHA) 2019 Annual Meeting and Expo in Philadelphia.